Drug intelligence / Profile preview

BK502

Development stage: Preclinical
Lead developer: ABVC BioPharma
Modality: Small Molecules

Overview

BK502 is a novel multi-component anti-diabetes drug. It is based on metformin and is designed to lower both blood sugar and lipids. BioKey acquired the exclusive rights to a U.S. patent application for BK502, and following its merger with American BriVision (ABVC), ABVC is involved in its development.

Targets

AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on BK502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BK502.

Explore the full profile